CompletedPhase 4ACTRN12611000573954

Adjunctive Medical Therapy with Oral Silodosin after Shock Wave Lithotripsy of Lower Ureteral Stone: A randomized controlled study

The efficacy of adjunctive medical therapy with daily oral silodosin(4 mg) after Shock Wave Lithotripsy of lower ureteral stone

Sponsor

Chung Jing Wang

Enrollment

45 participants

Start Date

Jun 1, 2010

Study Type

Interventional

Conditions

Lower ureteral stone after ESWL

Summary

a prospective study to evaluate the efficacy of oral silodosin 4 mg as adjunctive therapy after ESWL of lower ureteral stones

Eligibility

Sex: Both males and femalesMin Age: 20 YearssMax Age: 60 Yearss

Plain Language Summary

Simplified for easier understanding

This study evaluates whether taking silodosin after shock wave lithotripsy (a non-surgical treatment to break up kidney stones) helps pass lower ureteral stones more effectively. Participants aged 20 to 60 with stones between 4mm and 9mm are eligible. Those with urinary infections, diabetes, or low blood pressure are excluded.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Daily oral 4 mg silodosin for 2 weeks as adjunctive therapy after ESWL of lower ureteral stones

Locations(1)

Taiwan, Province Of China

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000573954